Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Cocaine Dependence, Opioid Dependency
Interventions: Disulfiram, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: RO6811135, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pain
Interventions: VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Depressive Disorder, Major Depressive Disorder, Bipolar Disorder, Post Traumatic Stress Disorder, Suicidal Ideation
Interventions: Perampanel 6 MG, Ketamine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Peripheral Vascular Diseases
Interventions: G-CSF, Placebo, Aspirin, Clopidogrel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Nocturia, Daytime Sleepiness
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Primary Dysmenorrhea
Interventions: VA111913 TS and placebo; Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Peoria, Arizona • Austin, Texas • Salt Lake City, Utah

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Menopause
Interventions: Ashoka Bark and Shatavari, Placebo; Dietary Supplement · Other
Lead sponsor: Vidya USA Corporation; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Bipolar Disorder
Interventions: Divalproex, Lamotrigine, Lithium; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 16 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 61
States / cities: Flagstaff, Arizona • Peoria, Arizona • Tucson, Arizona + 46 more

Conditions: Verruca Vulgaris, Warts, Common Wart
Interventions: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 9 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more

Conditions: Alzheimer Disease
Interventions: NP001, Placebo; Drug
Lead sponsor: Beau Nakamoto; Other
Eligibility: 55 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Clostridium Difficile Associated Disease
Interventions: C. difficile vaccine, C. difficile vaccine +adjuvant; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Pembroke Pines, Florida • South Miami, Florida • Overland Park, Kansas + 1 more

Conditions: Impotence
Interventions: Placebo, Viagra (sildenafil citrate); Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 30 Years and older · Male only
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 48
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 42 more

Conditions: Bronchoscopy
Interventions: Remimazolam, Placebo, Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 14
States / cities: Brandon, Florida • Sun City Center, Florida • Michigan City, Indiana + 10 more

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions: Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream, 1%, Placebo Cream; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 25
States / cities: Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more

Conditions: Chronic Hepatitis B
Interventions: ACH126, 433; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Pasadena, California + 8 more

Conditions: Pulmonary Cystic Fibrosis
Interventions: Placebo, QBW276; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: New York, New York • Dallas, Texas

Conditions: Alzheimer's Disease
Interventions: Acetaminophen, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

A Study of Single Dose RO6811135 in Healthy Volunteers

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Satavari and Ashoka for Menopause (SAM) Study

Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years

A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.

A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy

ONO-7746 Study in Healthy Adult Subjects

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis

Behavioral Expressions in Alzheimer's Disease